Jasper Therapeutics (JSPR) Competitors $3.97 +0.05 (+1.28%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.14 +0.17 (+4.28%) As of 04/17/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. IMMP, DRUG, FHTX, MBX, ITOS, CRVS, CKPT, YMAB, NVCT, and OCGNShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Immutep (IMMP), Bright Minds Biosciences (DRUG), Foghorn Therapeutics (FHTX), MBX Biosciences (MBX), iTeos Therapeutics (ITOS), Corvus Pharmaceuticals (CRVS), Checkpoint Therapeutics (CKPT), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Immutep Bright Minds Biosciences Foghorn Therapeutics MBX Biosciences iTeos Therapeutics Corvus Pharmaceuticals Checkpoint Therapeutics Y-mAbs Therapeutics Nuvectis Pharma Ocugen Jasper Therapeutics (NASDAQ:JSPR) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation. Which has preferable earnings & valuation, JSPR or IMMP? Immutep has higher revenue and earnings than Jasper Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$64.46M-$4.86-0.82Immutep$5.14M43.75-$28.01MN/AN/A Do analysts rate JSPR or IMMP? Jasper Therapeutics presently has a consensus price target of $62.50, suggesting a potential upside of 1,474.31%. Immutep has a consensus price target of $8.50, suggesting a potential upside of 451.95%. Given Jasper Therapeutics' higher probable upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Immutep.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to JSPR or IMMP? In the previous week, Jasper Therapeutics had 2 more articles in the media than Immutep. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Immutep. Jasper Therapeutics' average media sentiment score of 0.45 beat Immutep's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Jasper Therapeutics Neutral Immutep Neutral Is JSPR or IMMP more profitable? Immutep's return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -67.64% -58.53% Immutep N/A N/A N/A Do institutionals & insiders hold more shares of JSPR or IMMP? 79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 2.7% of Jasper Therapeutics shares are owned by insiders. Comparatively, 3.1% of Immutep shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer JSPR or IMMP? Immutep received 266 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 90.20% of users gave Jasper Therapeutics an outperform vote while only 72.56% of users gave Immutep an outperform vote. CompanyUnderperformOutperformJasper TherapeuticsOutperform Votes4690.20% Underperform Votes59.80%ImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has more volatility & risk, JSPR or IMMP? Jasper Therapeutics has a beta of 2.55, indicating that its stock price is 155% more volatile than the S&P 500. Comparatively, Immutep has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. SummaryJasper Therapeutics beats Immutep on 7 of the 13 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.64M$2.84B$5.30B$7.35BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-0.8430.4821.8017.80Price / SalesN/A441.91379.9697.74Price / CashN/A168.6838.2634.64Price / Book0.563.466.443.98Net Income-$64.46M-$72.06M$3.21B$247.73M7 Day Performance-4.57%2.58%2.87%1.81%1 Month Performance-23.95%-15.68%-8.63%-6.98%1 Year Performance-82.90%-26.09%11.46%1.37% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics1.9425 of 5 stars$3.97+1.3%$62.50+1,474.3%-83.3%$59.64MN/A-0.8420IMMPImmutep1.1009 of 5 stars$1.42-5.3%$8.50+498.6%-31.9%$206.69M$5.14M0.002,021Positive NewsDRUGBright Minds Biosciences2.4978 of 5 stars$29.25-8.7%$84.33+188.3%+2,804.4%$206.04MN/A-172.05N/ANews CoverageGap UpFHTXFoghorn Therapeutics2.23 of 5 stars$3.68+7.0%$13.17+257.8%-34.3%$204.65M$22.60M-1.92120MBXMBX Biosciences2.3903 of 5 stars$6.00-0.7%$37.25+520.8%N/A$200.54MN/A0.0036Gap DownITOSiTeos Therapeutics2.2491 of 5 stars$5.25-2.6%$25.75+390.5%-39.0%$200.52M$35M-1.6790Short Interest ↑CRVSCorvus Pharmaceuticals2.4673 of 5 stars$2.91+2.1%$15.67+438.4%+138.2%$198.28MN/A-3.1330Gap DownCKPTCheckpoint Therapeutics1.6338 of 5 stars$3.99-0.5%$4.33+8.6%+141.9%$194.84M$41,000.00-2.1710YMABY-mAbs Therapeutics3.5162 of 5 stars$4.28-5.7%$18.30+327.6%-69.0%$193.53M$87.69M-7.93150Short Interest ↓Positive NewsNVCTNuvectis Pharma2.0821 of 5 stars$8.24-0.1%$15.67+90.1%+31.1%$192.75MN/A-7.108Positive NewsGap UpOCGNOcugen1.2958 of 5 stars$0.65-2.0%$6.33+876.2%-52.8%$189.46M$4.06M-3.6080 Related Companies and Tools Related Companies Immutep Alternatives Bright Minds Biosciences Alternatives Foghorn Therapeutics Alternatives MBX Biosciences Alternatives iTeos Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Checkpoint Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Nuvectis Pharma Alternatives Ocugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JSPR Stock Free JSPR Stock Alerts